Journal article 1678 views 3144 downloads
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
The Lancet Diabetes & Endocrinology, Volume: 5, Issue: 4, Pages: 251 - 260
Swansea University Author:
Steve Bain
-
PDF | Accepted Manuscript
Released under the terms of a Creative Commons Attribution Non-Commercial No Derivatives License (CC-BY-NC-ND).
Download (866.67KB)
DOI (Published version): 10.1016/s2213-8587(17)30013-x
Abstract
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
| Published in: | The Lancet Diabetes & Endocrinology |
|---|---|
| ISSN: | 2213-8587 |
| Published: |
Elsevier BV
2017
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa31739 |
| College: |
Faculty of Medicine, Health and Life Sciences |
|---|---|
| Issue: |
4 |
| Start Page: |
251 |
| End Page: |
260 |